Shorter pill-free interval in combined oral contraceptives decreases follicular development

Contraception

Volumn 54, Issue 2, 1996, Pages 71-77

  Spona, Jürgen ^a,e   Elstein, Max ^b   Feichtinger, Wilfried ^c   Sullivan, Helen ^b   Lüdicke, Frank ^f   Muller U ^d   Düsterberg, Bernd ^d  

^a LAB 19   (Austria)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Institute for Sterility Treatment   (Austria)

^d BAYER PHARMA AG   (Germany)

^e Rudolfinerhaus ^*  (Austria)

^f UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

endogenous 17 estradiol; ethinylestradiol; gestodene; ovarian activity; pill free interval

Indexed keywords

ESTRADIOL; ETHINYLESTRADIOL; FOLLITROPIN; GESTODENE; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROGESTERONE;

ACNE; ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG MIXTURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTALGIA; MENSTRUAL CYCLE; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; OVARY FOLLICLE DEVELOPMENT; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SPOTTING; VERTIGO; VOMITING;

EID: 0030222154     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/0010-7824(96)00137-0     Document Type: Article

References (26)

1. 1. Inman WHW, Vessey MP, Westerhol B, Engelund MN. Thromboembolic diseases and steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Br Med J 1970;2:203-9.
2. 2. Jeffcoat TNA. RCOG Statement on oral contraceptives. Br Med J 1970;1:293.
3. 3. Gerstman BB, Piper JM, Tomita DK et al. Oral contraceptive estrogen dose and risk of deep venous thromboembolic disease. Am J Epidemiol 1991;133:32-6.
4. 4. Lidegaard O. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. B Med J 1993;306:956-63.
5. 5. Mishell DR Jr. Oral contraception: past, present and future perspectives. Int J Fertil 1991;36:7-18.
6. 6. Morris SE, Groom GV, Cameron ED, Buckingham MS, Everitt JM, Elstein M. Studies on low-dose contraceptives: plasma hormone changes in relation to deliberate pill ("Microgynon 30") omission. Contraception 1979; 20:61-9.
7. 7. Chowdhury V, Joshi UM, Gopalkrishna K, Betrabet S, Mehta S, Saxena BN. "Escape" ovulation in women due to missing low dose combination oral contraceptive pills. Contraception 1980;22:241-7.
8. 8. Wang E, Shi S, Cekan SZ, Landgren B-M, Diczfalusy E. Hormonal consequences of "missing the pill." Contraception 1982;26:45-66.
9. 9. Smith SK, Kirkman RJE, Arce BB, McNeilly AS, Loudon NB, Baird DT. The effects of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis. Contraception 1986;34:513-22.
10. 10. Killick SR, Bancroft K, Oelbaum S, Morris J, Elstein M. Extending the pill-free interval during combined oral contraception. Adv Contraception 1990;6:33-40.
11. 11. Fotherby K, Caldwell ADS. The new low dose oral contraceptives. J Obstet Gynecol 1994;14:327-32.
12. 12. Fitzgerald C, Feichtinger W, Spona J et al. Comparison of the effects of two monophasic low dose oral contraceptives on the inhibition of ovulation. Adv Contracep 1994;10:5-18.
13. 13. Elstein M, Bristow PG, Hewitt KJ et al. Effects of a low estrogen oral contraceptive on urinary excretion of luteinising hormone and ovarian steroids. Br Med J 1974; 1:11-3.
14. 14. Spellacy WN, Kalra PS, Buhi WC, Birk SA. Pituitary and ovarian responsiveness to graded gonadotropin releasing factor stimulation test in women using low-estrogen or regular type of oral contraceptive. Am J Obstet Gynecol 1980;137:109-15.
15. 15. Mall-Haefeli M, Werner-Zodrow I, Huber PR et al. Oral contraception and ovarian function. In: Runnebaum B, Rabe T, Kiesel L, eds. Female Contraception. Berlin: Springer-Verlag 1988:97-105.
16. 16. Killick S, Eyong E, Elstein M. Ovarian follicular development in oral contraceptive cycles. Fert Steril 1987; 48:409-13.
17. 17. Hamilton CJCM, Hoogland HJ. Longitudinal ultrasonographic studies of the ovarian suppressive activity of a low-dose triphasic oral contraceptive during correct and incorrect pill intake. Am J Obstet Gynecol 1989;161: 1159-62.
18. 18. Tayob Y, Adams J, Jacobs HS et al. Ultrasound demonstration of an increased incidence in functional ovarian cysts in progestogen-only pill users. Br J Obstet Gynecol 1985;92:1003-9.
19. 19. Finlay IG, Scott MBG. Patterns of contraceptive pill taking in an inner city practice. Br Med J 1986;293: 601-2.
20. 20. Belaish-Allart J, Dufetre C, Allart JP, De Monzon J. Comparison of transvaginal and transabdominal ultrasound for monitoring follicular development in an in vitro fertilisation program. Hum Reprod 1991;6:688-9.
21. 21. Elstein M, Morris SE, Groom GB et al. Studies on low dose oral contraceptives: cervical mucus and plasma hormone changes in relation to circulating d-norgestrel and ethinylestradiol concentrations. Fertil Steril 1976; 27:892-9.
22. 22. Lahteenmaki P. Immediate post abortal contraception with a microdose combined preparation: gonadotrophin, estradiol and progesterone levels during the last treatment cycle and after discontinuation of oral contraceptives. Contraception 1978;17:297-307.
23. 23. Brenner PF, Mishell DR Jr, Stanczyk FZ et al. Serum levels of d-norgestrel, LH, FSH, estradiol and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel. Am J Obstet Gynecol 1977;129:133-40.
24. 24. Landgren BM, Diczfalusy E. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles. Contraception 1984;29:437-46.
25. 25. Van der Vange N, Bruinse HW, Tureel et al. Ovarian activity and low dose oral contraceptives. Adv Contracept 1985;1:249-55.
26. 26. Hoogland HJ, Skouby SO. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception 1993;47:583-90.